First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Sex-specific difference for melanoma from immunotherapy advancement.Frontiers in oncology · 2024
   Article
2. Immunotherapy in melanoma: advances, pitfalls, and future perspectives.Frontiers in molecular biosciences · 2024
   Review
3. Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma.Frontiers in molecular biosciences · 2022
   Review
4. Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2021
   Article
5. PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake.Frontiers in pharmacology · 2020
   Review
6. Establishment of a 5-gene risk model related to regulatory T cells for predicting gastric cancer prognosis.Cancer cell international · 2020
   Article
7. Time for radioimmunotherapy: an overview to bring improvements in clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
   Review
8. The Dosage of the Derivative ofBioMed research international · 2019
   Article
9. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.Frontiers in immunology · 2019
   Review
10. Invariant NKT Cell-Mediated Modulation of ILC1s as a Tool for Mucosal Immune Intervention.Frontiers in immunology · 2019
    Article
11. Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer.Journal of Cancer · 2019
    Article

Corrections and comments

• Comment on
  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.2017

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as